NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT02611024 2025-07-09Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsPharmaMarPhase 1/2 Completed316 enrolled
NCT02279433 2025-06-24A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bNuvation Bio Inc.Phase 1 Completed46 enrolled
NCT01794793 2024-10-01Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesRECORDATI GROUPPhase 4 Completed337 enrolled 8 charts
NCT01789281 2021-06-11Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.NovartisPhase 4 Completed34 enrolled 8 charts
NCT01970540 2020-03-09Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid TumorsPharmaMarPhase 1 Completed122 enrolled 19 charts
NCT01525550 2019-07-30A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsPfizerPhase 4 Completed106 enrolled 26 charts
NCT02063958 2018-07-30Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine TumorsEsanex Inc.Phase 1 Completed19 enrolled
NCT00050349 2017-03-01EPO906 in Carcinoid and Other Neuroendocrine TumorsNovartisPhase 2 Completed33 enrolled
NCT00753415 2015-03-17A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)Merck Sharp & Dohme LLCPhase 1 Completed37 enrolled 10 charts
NCT00363051 2013-05-10Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyNovartisPhase 2 Completed160 enrolled 17 charts